Tailored Treatments for Premenopausal Women with Endocrine Responsive Breast Cancer.

为患有内分泌反应性乳腺癌的绝经前女性量身定制治疗。

• 批准号: nhmrc : 510788
• 负责人: A/Pr Jacqueline Chirgwin
• 金额: $ 19.95万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/tailored-treatments-premenopausal-breast-cancer/98631
• 关键词: Tailored; Treatments; Premenopausal; Women; Endocrine

For women <50yrs with ER+ breast cancer adjuvant treatment (AT) with chemotherapy (CT), tamoxifen and ovarian function suppression (OFS) are each effective and reduce recurrence. Combining 2 treatments is more effective than 1, but it is unclear if combining 3 provides any extra benefit. 2 trials,SOFT and TEXT, aim to answer this question. SOFT tests the benefit of adding OFS for very young women who remain premenopausal after CT, TEXT is for women who should receive OFS from the start of AT.

对于ER+乳腺癌辅助治疗（AT）+化疗（CT）的50岁女性，他莫昔芬和卵巢功能抑制（OFS）均有效并可减少复发。结合2种治疗方法比1种更有效，但目前尚不清楚结合3种治疗方法是否会带来额外的益处。SOFT和TEXT两项试验旨在回答这个问题。SOFT测试了在CT后仍处于绝经前的非常年轻的女性中添加OFS的益处，TEXT适用于从AT开始就应接受OFS的女性。